Bài viết

Define “better” before counting wavelengths

A comparison needs one clear outcome: fewer acne lesions, a change in measured skin roughness, or a change in a wrinkle assessment, for example. Improvement in one outcome does not establish improvement in another. Photobiomodulation (PBM) is not a single interchangeable treatment: FDA’s PBM draft guidance identifies wavelength, irradiance, fluence, pulsing, and spot size as relevant to outcomes. [3]

Three different questions are often compressed into the phrase “multi wavelength red light”:

• Does the complete mixed-band treatment help? A suitable comparison with a control can address this.
• Does the mixed treatment outperform a single band? That requires a direct comparison with the relevant single-band treatment.
• Do the bands have a synergistic effect? That requires evidence of an interaction beyond the improvement expected from the components under a defined analytical model.

These are questions about study design, not synonyms. A combination beating an inactive control answers the first question; it does not, by itself, answer the other two. A proposed cellular mechanism is a reason to investigate a combination, not proof of a visible benefit in people.

Adding light is different from adding benefit

Irradiance describes light power received per unit surface area. Radiant exposure describes accumulated incident energy per unit area. For steady output, exposure equals irradiance multiplied by time; for changing output, it must be accumulated over time. These are physical accounting relationships, not treatment recommendations or measurements of energy absorbed inside tissue. [3]

For non-overlapping measured bands at the same surface location and over the same interval, their incident exposures add to a total. But that total conceals how much belongs to each band. Equal total exposure does not mean equal red exposure, and equal red exposure does not mean equal total exposure.

This is why a headline specification such as “combined irradiance” is incomplete for evaluating a combination. Ask for output by band and by operating mode, measured at the intended treatment surface, with measurement conditions and uncertainty stated. A specification describes light delivery; a matching human study is still needed to assess benefit.

Matched controls depend on the question

To test whether adding a band helps an existing red treatment, preserve the red component and document the added exposure. To compare two complete regimens at the same total exposure, document how the energy is distributed. Neither arrangement is automatically sufficient to prove synergy. The comparison should also account for coverage, positioning, pulsing, treatment schedule, participant selection, accompanying skin care, and assessment timing.

This is a framework for reading research, not permission to change a device’s settings. Mixing results from unrelated studies leaves these variables uncontrolled.

The 2014 trial: a useful comparison with narrow applicability

Wunsch and Matuschka included 136 volunteers. Four active groups received 30 sessions using large-area gas-discharge lamps, not LED masks. The comparison involved a broad 570–850 nm spectrum and lamps emitting predominantly in the 611–650 nm red range. Exposure was normalized to approximately 9 J/cm² in that red window; total exposure was not matched. The authors found no significant advantage for the broader spectrum on the assessed outcomes. [1]

The red comparator was not a single monochromatic wavelength. Duration, irradiance, and geometry differed among units. Treatment groups were randomized, but the untreated control group was recruited separately, mainly from company employees, without randomization; there was no sham treatment. The sponsor funded the study and paid the investigators. [1]

Measured outcomes included skin roughness, an ultrasound collagen intensity score, photographs, and subjective skin assessments. They do not establish guaranteed lifting. This study challenges an automatic “broader is better” assumption for its tested conditions. It neither validates contemporary LED combinations nor proves that all single-band and mixed-band treatments are equivalent. [1]

Acne research does not create a universal wavelength ranking

A 2025 JAMA Dermatology systematic review included six randomized studies with 216 participants who had mild-to-moderate acne. Devices used red, blue, or combined light. The review reported benefit compared with controls and discussed a study in which red plus blue produced greater improvement than blue alone. It also identified differences in light sources, exposure, and study duration that complicated comparisons. [2]

That finding deserves attention; it does not establish that every additional band improves every skin concern. Acne lesion counts are different from wrinkle outcomes, and red plus blue is different from red plus near-infrared. The review calls for further comparisons of wavelengths and treatment parameters and cautions that results may not generalize to other devices. Its pooled improvement is not a numerical estimate of synergy. [2]

Keep the conclusion attached to the studied target, combination, and comparator. “A particular combination has supporting acne evidence” and “more wavelengths are always better” are very different claims.

What a claimed synergy needs to demonstrate

Use this checklist to distinguish a testable claim from a band count:

1. A defined target. Which population, skin concern, and outcome were evaluated?
2. A complete exposure description. What did each band deliver, and were the bands simultaneous or sequential?
3. Relevant component comparisons. Were the individual components and combination tested with suitable controls, rather than comparing the combination only with no treatment?
4. A stated meaning of synergy. Did the analysis test an interaction under a justified model, or merely report that the combination improved?
5. A credible between-group result. Was there a direct estimate of the difference and its uncertainty, rather than one significant within-group result and one nonsignificant result?
6. A match to the actual device. Do its spectrum, delivery geometry, modes, and intended use match the intervention studied?
7. Safety and reproducibility. Were adverse events, follow-up, missing data, and funding disclosed? Is there independent confirmation?

These are evidence-appraisal questions, not a claim that every study must use one universal protocol. FDA’s January 2023 PBM guidance remains labeled a draft, with nonbinding recommendations and “not for implementation” status. Its device-description and clinical-study sections provide useful context, but its scope concerns specified US class II PBM medical devices; some low-risk general-wellness products may fall outside it. It is not certification of a combination or a consumer treatment schedule. [3]

Common shortcuts that do not establish superiority

• “More colors cover more problems.” Each claimed outcome still needs matching evidence.
• “Both wavelengths have studies, so their combination is proven.” Separate studies do not test their interaction.
• “The mixed group improved significantly.” Improvement within that group does not establish superiority over the single-band group.
• “The total dose matches.” A total does not preserve the exposure delivered in each band.

Frequently asked questions

Does a list of several wavelengths mean they run together?

No. A list alone does not tell you which emitters operate in a particular mode or whether output is simultaneous or sequential. Check the mode description and corresponding output documentation; do not assume the maximum listed output applies to every setting.

Can I combine two single-band devices to recreate a studied treatment?

The combination is not established as equivalent merely because the wavelength labels match. Positioning, exposure distribution, timing, and safety provisions would also need to match. Do not construct a combined regimen from separate device claims.

If a study finds no difference, are the treatments equivalent?

Not necessarily. Failure to detect a difference can reflect limited precision. Demonstrating equivalence requires an appropriate design and a prespecified acceptable difference; a nonsignificant superiority comparison alone does not do that.

Does evidence about a light-based procedure with a sensitizing drug apply?

A protocol using an added photosensitizing agent is a different intervention from ordinary LED exposure. For this comparison, evidence must match the actual intervention; do not import results from photodynamic therapy, UV treatment, IPL, lasers, bright-light boxes, or infrared heating into a claim about a cosmetic LED combination.

Compare the claim with the study, not the number of bands

The decisive question is whether the complete treatment has demonstrated the claimed outcome against an informative comparator. Without that match, a longer wavelength list remains a specification—not evidence of greater benefit.